PTN

Palatin Technologies, Inc. To Report Third Quarter Fiscal Year 2014 Results

[PR Newswire] – CRANBURY, N.J., May 9, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2014 operating results on Tuesday, May 13, 2014 before the open of the … moreView todays social media effects on PTNView the latest stocks trending across Twitter. Click to view dashboardSee who Palatin is hiring next, click […]

Palatin Technologies Presents at the American Psychiatric Association (APA)

[PR Newswire] – CRANBURY, N.J., May 6, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of moreView todays social media effects on PTNView the latest stocks trending across Twitter. Click to view dashboardSee who Palatin is hiring next, click here to […]

7:34 am Palatin Technologies presents positive new data analyses demonstrating efficacy of bremelanotide in female hypoactive sexual desire disorder

moreView todays social media effects on PTNView the latest stocks trending across Twitter. Click to view dashboardSee who Palatin is hiring next, click here to view […]

Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder

[PR Newswire] – CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements … moreView todays social media effects on PTNView the latest stocks trending across Twitter. Click to view dashboardSee who Palatin is hiring next, click here to view […]

PALATIN TECHNOLOGIES INC Financials

moreView todays social media effects on PTNView the latest stocks trending across Twitter. Click to view dashboardSee who Palatin is hiring next, click here to view […]

Palatin Technologies’ CEO Discusses F2Q2014 Results – Earnings Call Transcript

[at Seeking Alpha] – Steve Wills Thank you, Carl, and good morning, everyone. Regarding operational highlights pivotal Phase 3 clinical trials of Bremelanotide for the treatment of female sexual dysfunction are anticipated … moreView todays social media effects on PTNView the latest stocks trending across Twitter. Click to view dashboardSee who Palatin is hiring next, click here to view […]